Harm Wienbergen
Research Subjects
Harm Wienbergen has a total of 206 co-authors. Here are the top co-authors by number of shared publications:
Rainer Hambrecht
18 shared publicationsAndreas Fach
Bremen Institute for Heart and Circulation Research (BIHKF) , Senator-Weßling-Str. 2, Bremen 28277
16 shared publicationsJochen Senges
Stiftung Institut für Herzinfarktforschung Ludwigshafen, Ludwigshafen am Rhein, Germany
11 shared publicationsJohannes Schmucker
Bremen Institute for Heart and Circulation Research (BIHKF), Bremen, Germany
11 shared publicationsRico Osteresch
Bremen Institute for Heart and Circulation Research (BIHKF) , Senator-Weßling-Str. 2, Bremen 28277
8 shared publications- Rainer Hambrecht
Bremer Institut für Herz- und Kreislaufforschung (BIHKF), Klinikum Links der Weser, Bremen, Deutschland
7 shared publications
Latest Publications
- 13 July 2026
- Published by Georg Thieme Verlag KG in DMW - Deutsche Medizinische Wochenschrift
- Vol. 151 (14) , 773-778
[Heart health must not be a question of socioeconomic status].
It is not enough to treat cholesterol and blood pressure alone to prevent heart attacks; social causes must also be addressed: unequal educational opportunities, unemployment, and a lack of prevention. The extent of the impact of these factors can be seen in the federal state of Bremen. For this reason, targeted strategies were developed there ("Bremen model") to provide heart health from being a matter of income or background.
- 13 July 2026
- Published by Georg Thieme Verlag KG in DMW - Deutsche Medizinische Wochenschrift
- Vol. 151 (14) , 773-778
[Heart health must not be a question of socioeconomic status].
It is not enough to treat cholesterol and blood pressure alone to prevent heart attacks; social causes must also be addressed: unequal educational opportunities, unemployment, and a lack of prevention. The extent of the impact of these factors can be seen in the federal state of Bremen. For this reason, targeted strategies were developed there ("Bremen model") to provide heart health from being a matter of income or background.
- 31 October 2025
- Published by Oxford University Press (OUP) in European Journal of Preventive Cardiology
- Vol. 33 (14) , 2685-2686
Authors’ reply to the comment by Zhuang and Jin on ‘Severe obesity in patients with ST-segment–elevation myocardial infarction (STEMI): association with age, temporal trends, and clinical outcomes’
- 31 October 2025
- Published by Oxford University Press (OUP) in European Journal of Preventive Cardiology
- Vol. 33 (14) , 2685-2686
Authors’ reply to the comment by Zhuang and Jin on ‘Severe obesity in patients with ST-segment–elevation myocardial infarction (STEMI): association with age, temporal trends, and clinical outcomes’
- 31 July 2025
- Published by Oxford University Press (OUP) in European Journal of Preventive Cardiology
- Vol. 33 (14) , 2595-2609
Severe obesity in patients with ST-elevation myocardial infarctions: association with age, temporal trends, and clinical outcomes
Aims: This study aimed to determine the prevalence of severe obesity [body mass index (BMI) ≥ 40 kg/m²] among patients with ST-elevation myocardial infarction (STEMI) and clarify its association with age, temporal trends, and outcomes. Methods and results: Consecutive patients admitted to a German heart centre between 2006 and 2022 for STEMI were categorized into five BMI groups according to the World Health Organization classification. Among the 11 629 STEMI patients, 269 (2.3%) had severe obesity. These patients were more likely to be female, have diabetes, and were on average 8.6 years younger than normal-weight patients (57.8 ± 12 vs. 66.4 ± 14 years, P < 0.01). The prevalence of severe obesity increased from 1.9 to 2.6% (2006–13 vs. 2013–22, P = 0.014), with the increase being a greater in females than in males (2.5–3.7%, P = 0.052). In younger patients (<55 years), prevalence rates increased by 128% in females (4.9–11.3%, P < 0.01) and 71% in men (2.2–3.7%, P < 0.01). Severe obesity did not affect treatment outcomes or in-hospital adverse event rates but was associated with higher 30-day [14.2% vs. 9.2%; adjusted hazard ratio (HR), 1.99; 95% confidence interval (CI), 1.4–3.0; P < 0.01] and 5-year mortality rates (30.6% vs. 20.6%; adjusted HR, 2.03; 95% CI, 1.4–2.9; P < 0.01). Conclusion: The significant increase in the prevalence of severe obesity among patients with STEMI, particularly among females and younger individuals, underscores the urgent need for more effective prevention and treatment strategies to improve their long-term prognosis.
- 31 July 2025
- Published by Oxford University Press (OUP) in European Journal of Preventive Cardiology
- Vol. 33 (14) , 2595-2609
Severe obesity in patients with ST-elevation myocardial infarctions: association with age, temporal trends, and clinical outcomes
Aims: This study aimed to determine the prevalence of severe obesity [body mass index (BMI) ≥ 40 kg/m²] among patients with ST-elevation myocardial infarction (STEMI) and clarify its association with age, temporal trends, and outcomes. Methods and results: Consecutive patients admitted to a German heart centre between 2006 and 2022 for STEMI were categorized into five BMI groups according to the World Health Organization classification. Among the 11 629 STEMI patients, 269 (2.3%) had severe obesity. These patients were more likely to be female, have diabetes, and were on average 8.6 years younger than normal-weight patients (57.8 ± 12 vs. 66.4 ± 14 years, P < 0.01). The prevalence of severe obesity increased from 1.9 to 2.6% (2006–13 vs. 2013–22, P = 0.014), with the increase being a greater in females than in males (2.5–3.7%, P = 0.052). In younger patients (<55 years), prevalence rates increased by 128% in females (4.9–11.3%, P < 0.01) and 71% in men (2.2–3.7%, P < 0.01). Severe obesity did not affect treatment outcomes or in-hospital adverse event rates but was associated with higher 30-day [14.2% vs. 9.2%; adjusted hazard ratio (HR), 1.99; 95% confidence interval (CI), 1.4–3.0; P < 0.01] and 5-year mortality rates (30.6% vs. 20.6%; adjusted HR, 2.03; 95% CI, 1.4–2.9; P < 0.01). Conclusion: The significant increase in the prevalence of severe obesity among patients with STEMI, particularly among females and younger individuals, underscores the urgent need for more effective prevention and treatment strategies to improve their long-term prognosis.
- 28 March 2025
- Published by Springer Nature in Herz
- Vol. 50 (3) , 217-226
Update kardiovaskuläre Prävention 2025
- 28 March 2025
- Published by Springer Nature in Herz
- Vol. 50 (3) , 217-226
Update kardiovaskuläre Prävention 2025
- 28 March 2025
[Update on cardiovascular prevention 2025].
Despite an expensive healthcare system Germany performs poorly with respect to life-expectancy compared to other countries, for which cardiovascular diseases and deficits in cardiovascular prevention in particular are responsible. The basis of cardiovascular prevention is a healthy lifestyle with regular physical exercise, a predominantly plant-based diet, nonsmoking, good sleep and mental health. In many cases additional lipid-lowering, antidiabetic and antihypertensive medications are necessary. Recent studies have proven the prognostic effects of different groups of medications, such as proprotein convertase subtilisin/kexin type 9 (PCSK9) inhibitors, sodium-glucose transporter 2 (SGLT2) inhibitors and glucagon-like peptide 1 (GLP-1) receptor agonists, in the appropriate indication areas. To improve the cardiovascular prevention in Germany, intensified public efforts are crucial. In addition, individual support of patients is effective for long-term preventive measures. To achieve this healthcare professionals must be trained (physicians, cardiovascular prevention assistants), who can sustainably support patients in lifestyle modifications and medicinal prevention.
- 28 March 2025
[Update on cardiovascular prevention 2025].
Despite an expensive healthcare system Germany performs poorly with respect to life-expectancy compared to other countries, for which cardiovascular diseases and deficits in cardiovascular prevention in particular are responsible. The basis of cardiovascular prevention is a healthy lifestyle with regular physical exercise, a predominantly plant-based diet, nonsmoking, good sleep and mental health. In many cases additional lipid-lowering, antidiabetic and antihypertensive medications are necessary. Recent studies have proven the prognostic effects of different groups of medications, such as proprotein convertase subtilisin/kexin type 9 (PCSK9) inhibitors, sodium-glucose transporter 2 (SGLT2) inhibitors and glucagon-like peptide 1 (GLP-1) receptor agonists, in the appropriate indication areas. To improve the cardiovascular prevention in Germany, intensified public efforts are crucial. In addition, individual support of patients is effective for long-term preventive measures. To achieve this healthcare professionals must be trained (physicians, cardiovascular prevention assistants), who can sustainably support patients in lifestyle modifications and medicinal prevention.
- Open Access
- 1 September 2024
- Published by Oxford University Press (OUP) in European Heart Journal
- Vol. 45 (47) , 5058-5067
Glycoprotein IIb/IIIa inhibitors in acute myocardial infarction and angiographic microvascular obstruction: the REVERSE-FLOW trial
Background and Aims: Glycoprotein (GP) IIb/IIIa inhibitors are recommended in acute myocardial infarction (AMI) for bailout treatment in case of angiographic microvascular obstruction (MVO), also termed no-reflow phenomenon, after percutaneous coronary intervention (PCI) with, however, lacking evidence (class IIa, level C). Methods: The investigator-initiated, international, multicentre REVERSE-FLOW trial randomized 120 patients with AMI and thrombolysis in myocardial infarction flow grade ≤ 2 after primary PCI to optimal medical therapy with or without GP IIb/IIIa inhibitor. The primary endpoint was infarct size [percentage of left ventricular (LV) mass assessed by cardiac magnetic resonance (CMR). Secondary endpoints included CMR-derived MVO and 30-day adverse clinical events. The trial is registered with ClinicalTrials.gov: NCT02739711. Results: The population was predominantly male (76.7%) with a median age of 66 years and ST-elevation myocardial infarction in 73.3% of patients. Clinical and angiographic characteristics were well balanced between the cohorts. Patients in the treatment group (n = 62) received eptifibatide (n = 41) or tirofiban (n = 21). Infarct size assessed by CMR imaging was similar in both study groups [25.4% of LV mass (%LV) vs. 25.2%LV; P = .386]. However, the number of patients with evidence of CMR-derived MVO (74.5% vs. 92.2%; P = .017) and the extent of MVO (2.1%LV vs. 3.4%LV; P = .025) were significantly reduced in the GP IIb/IIIa inhibitor group compared with controls. Thirty-day outcome showed an increased bleeding risk after GP IIb/IIIa inhibitor administration restricted to non–life-threatening bleedings (22.6% vs. 6.9%; P = .016) without differences in all-cause mortality (4.8% vs. 3.4%; P = .703). Conclusions: Bailout GP IIb/IIIa inhibition in AMI patients with angiographic MVO failed to reduce the primary endpoint infarct size but decreased CMR-derived MVO and led to an increase in non-fatal bleeding events.
- 1 September 2024
- Published by Oxford University Press (OUP) in European Heart Journal
- Vol. 45 (47) , 5058-5067
Open AccessGlycoprotein IIb/IIIa inhibitors in acute myocardial infarction and angiographic microvascular obstruction: the REVERSE-FLOW trial
Background and Aims: Glycoprotein (GP) IIb/IIIa inhibitors are recommended in acute myocardial infarction (AMI) for bailout treatment in case of angiographic microvascular obstruction (MVO), also termed no-reflow phenomenon, after percutaneous coronary intervention (PCI) with, however, lacking evidence (class IIa, level C). Methods: The investigator-initiated, international, multicentre REVERSE-FLOW trial randomized 120 patients with AMI and thrombolysis in myocardial infarction flow grade ≤ 2 after primary PCI to optimal medical therapy with or without GP IIb/IIIa inhibitor. The primary endpoint was infarct size [percentage of left ventricular (LV) mass assessed by cardiac magnetic resonance (CMR). Secondary endpoints included CMR-derived MVO and 30-day adverse clinical events. The trial is registered with ClinicalTrials.gov: NCT02739711. Results: The population was predominantly male (76.7%) with a median age of 66 years and ST-elevation myocardial infarction in 73.3% of patients. Clinical and angiographic characteristics were well balanced between the cohorts. Patients in the treatment group (n = 62) received eptifibatide (n = 41) or tirofiban (n = 21). Infarct size assessed by CMR imaging was similar in both study groups [25.4% of LV mass (%LV) vs. 25.2%LV; P = .386]. However, the number of patients with evidence of CMR-derived MVO (74.5% vs. 92.2%; P = .017) and the extent of MVO (2.1%LV vs. 3.4%LV; P = .025) were significantly reduced in the GP IIb/IIIa inhibitor group compared with controls. Thirty-day outcome showed an increased bleeding risk after GP IIb/IIIa inhibitor administration restricted to non–life-threatening bleedings (22.6% vs. 6.9%; P = .016) without differences in all-cause mortality (4.8% vs. 3.4%; P = .703). Conclusions: Bailout GP IIb/IIIa inhibition in AMI patients with angiographic MVO failed to reduce the primary endpoint infarct size but decreased CMR-derived MVO and led to an increase in non-fatal bleeding events.
- 19 June 2024
- Published by Springer Nature in Clinical Research in Cardiology
- Vol. 114 (6) , 719-728
Long-term risk factor management and adverse events in patients with early-onset myocardial infarction—a “real-world” study
Background International guidelines emphasize the importance of preventive efforts after early-onset myocardial infarction (EOMI); however, data on “real-world” long-term risk factor management and adverse event rates in this special patient group is scarce. Methods In this German registry study, 301 patients with MI aged ≤ 45 years were investigated. Risk factor control was assessed at the time of index MI and after 1 year. Major adverse cardiac and cerebrovascular events (MACCE) and its predictors were analyzed during long-term follow-up (median duration 49 months). Results A majority of patients with EOMI presented with insufficient risk factor control, even during 1-year follow-up. After 1-year 42% of patients were persistent smokers; 74% were physically inactive. The rate of obesity increased significantly from index MI (41%) to 1-year follow-up (46%, p = 0.03) as well as the rate of dysglycemia (index MI: 40%; 1-year follow-up: 51%, p < 0.01) and diabetes mellitus (index MI: 20%; 1-year follow-up: 24%, p < 0.01). 66% of the patients with diabetes mellitus had unsatisfactory HbA1c after 1 year; 69% of the patients did not attain guideline-recommended lipid targets. The rate of MACCE during long-term follow-up was 20% (incidence rate 0.05 per person-year). In a multivariable analysis smoking (HR 2.2, HR 1.3–3.7, p < 0.01) and physical inactivity (HR 2.8, HR 1.2–6.7, p = 0.02) were significant predictors for the occurrence of MACCE. Conclusion Insufficient long-term risk factor control was common in patients with EOMI and was associated with an elevated rate of MACCE. The study reveals that better strategies for prevention in young patients are crucially needed. Graphical Abstract
- 19 June 2024
- Published by Springer Nature in Clinical Research in Cardiology
- Vol. 114 (6) , 719-728
Long-term risk factor management and adverse events in patients with early-onset myocardial infarction—a “real-world” study
Background International guidelines emphasize the importance of preventive efforts after early-onset myocardial infarction (EOMI); however, data on “real-world” long-term risk factor management and adverse event rates in this special patient group is scarce. Methods In this German registry study, 301 patients with MI aged ≤ 45 years were investigated. Risk factor control was assessed at the time of index MI and after 1 year. Major adverse cardiac and cerebrovascular events (MACCE) and its predictors were analyzed during long-term follow-up (median duration 49 months). Results A majority of patients with EOMI presented with insufficient risk factor control, even during 1-year follow-up. After 1-year 42% of patients were persistent smokers; 74% were physically inactive. The rate of obesity increased significantly from index MI (41%) to 1-year follow-up (46%, p = 0.03) as well as the rate of dysglycemia (index MI: 40%; 1-year follow-up: 51%, p < 0.01) and diabetes mellitus (index MI: 20%; 1-year follow-up: 24%, p < 0.01). 66% of the patients with diabetes mellitus had unsatisfactory HbA1c after 1 year; 69% of the patients did not attain guideline-recommended lipid targets. The rate of MACCE during long-term follow-up was 20% (incidence rate 0.05 per person-year). In a multivariable analysis smoking (HR 2.2, HR 1.3–3.7, p < 0.01) and physical inactivity (HR 2.8, HR 1.2–6.7, p = 0.02) were significant predictors for the occurrence of MACCE. Conclusion Insufficient long-term risk factor control was common in patients with EOMI and was associated with an elevated rate of MACCE. The study reveals that better strategies for prevention in young patients are crucially needed. Graphical Abstract
- 31 August 2023
- Published by Springer Nature in Clinical Research in Cardiology
- Vol. 114 (6) , 690-699
Impact of educational attainment on preventive efforts after myocardial infarction: results of the IPP and NET-IPP trials
Aims Educational attainment might impact secondary prevention after myocardial infarction (MI). The purpose of the present study was to compare the rate of risk factors and the efficacy of an intensive prevention program (IPP), performed by prevention assistants and supervised by physicians, in patients with MI and different levels of education. Methods In this post hoc analysis of the multicenter IPP and NET-IPP trials, patients with MI were stratified into two groups according to educational attainment: no “Abitur” (no A) vs. “Abitur” or university degree (AUD). The groups were compared at the time of index MI and after 12-month IPP vs. usual care. Results Out of n = 462 patients with MI, 76.0% had no A and 24.0% had AUD. At the time of index, MI rates of obesity (OR 2.4; 95%CI 1.4–4.0), smoking (OR 2.2, 95%CI 1.4–3.6), and physical inactivity (OR 1.6; 95%CI 1.0–2.5) were significantly elevated in patients with no A. At 12 months after index MI, larger improvements of the risk factors smoking and physical inactivity were observed in patients with IPP and no A than in patients with IPP and AUD or with usual care. LDL cholesterol levels were reduced by IPP compared to usual care, with no difference between no A vs. AUD. A matched-pair analysis revealed that high baseline risk was an important reason for the large risk factor reductions in patients with IPP and no A. Conclusion The study demonstrates that patients with MI and lower educational level have an increased rate of lifestyle-related risk factors and a 12-month IPP, which is primarily performed by non-physician prevention assistants, is effective to improve prevention in this high-risk cohort. Graphical Abstract
- 31 August 2023
- Published by Springer Nature in Clinical Research in Cardiology
- Vol. 114 (6) , 690-699
Impact of educational attainment on preventive efforts after myocardial infarction: results of the IPP and NET-IPP trials
Aims Educational attainment might impact secondary prevention after myocardial infarction (MI). The purpose of the present study was to compare the rate of risk factors and the efficacy of an intensive prevention program (IPP), performed by prevention assistants and supervised by physicians, in patients with MI and different levels of education. Methods In this post hoc analysis of the multicenter IPP and NET-IPP trials, patients with MI were stratified into two groups according to educational attainment: no “Abitur” (no A) vs. “Abitur” or university degree (AUD). The groups were compared at the time of index MI and after 12-month IPP vs. usual care. Results Out of n = 462 patients with MI, 76.0% had no A and 24.0% had AUD. At the time of index, MI rates of obesity (OR 2.4; 95%CI 1.4–4.0), smoking (OR 2.2, 95%CI 1.4–3.6), and physical inactivity (OR 1.6; 95%CI 1.0–2.5) were significantly elevated in patients with no A. At 12 months after index MI, larger improvements of the risk factors smoking and physical inactivity were observed in patients with IPP and no A than in patients with IPP and AUD or with usual care. LDL cholesterol levels were reduced by IPP compared to usual care, with no difference between no A vs. AUD. A matched-pair analysis revealed that high baseline risk was an important reason for the large risk factor reductions in patients with IPP and no A. Conclusion The study demonstrates that patients with MI and lower educational level have an increased rate of lifestyle-related risk factors and a 12-month IPP, which is primarily performed by non-physician prevention assistants, is effective to improve prevention in this high-risk cohort. Graphical Abstract
- 4 August 2023
- Published by Georg Thieme Verlag KG in DMW - Deutsche Medizinische Wochenschrift
- Vol. 148 (16) , 1009-1019
Allgemeine Abschätzung des kardiovaskulären Risikos
Validierte Scores zur Bestimmung des kardiovaskulären Risikos erlauben es, die Individuen zu identifizieren, die von präventiven Interventionen am meisten profitieren. Daneben verdeutlichen sie auf individueller Basis die Folgen ungesunden Lebensstils und die Risikoreduktion durch zielgerichtete Anpassung (z.B. LDL-C-Reduktion). Scores sind damit ein wichtiges Instrument zur Motivation von Patienten, ihr Risikoprofil zu verbessern. The assessment of individual cardiovascular disease risk (CVD) is essential for a cost-effective prevention of cardiovascular morbidity and mortality. While almost half of the population have a very low CVD risk approximately 1/5th of the population have a CVD risk >20% over the next 10 years. Modern risk scores like the ESC-SCORE2 help to identify those in need of intensified preventive efforts based on basic risk factors like smoking, systolic blood pressure, total cholesterol, age, and sex. According to current ESC-guidelines all men >45 years and all women >55 years should be assessed with SCORE2, which is the best calibrated and validated scoring system for Europe. The calculation of total cardiovascular risk also permits to calculate an individual heart-age, which makes it easier for the individual patient to understand his own risk profile. Most current risk estimation systems can be accessed online under u-prevent.com/calculators. Article published online: 04 August 2023 © 2023. Thieme. All rights reserved. Georg Thieme Verlag KG Rüdigerstraße 14, 70469 Stuttgart, Germany
- 4 August 2023
- Published by Georg Thieme Verlag KG in DMW - Deutsche Medizinische Wochenschrift
- Vol. 148 (16) , 1009-1019
Allgemeine Abschätzung des kardiovaskulären Risikos
Validierte Scores zur Bestimmung des kardiovaskulären Risikos erlauben es, die Individuen zu identifizieren, die von präventiven Interventionen am meisten profitieren. Daneben verdeutlichen sie auf individueller Basis die Folgen ungesunden Lebensstils und die Risikoreduktion durch zielgerichtete Anpassung (z.B. LDL-C-Reduktion). Scores sind damit ein wichtiges Instrument zur Motivation von Patienten, ihr Risikoprofil zu verbessern. The assessment of individual cardiovascular disease risk (CVD) is essential for a cost-effective prevention of cardiovascular morbidity and mortality. While almost half of the population have a very low CVD risk approximately 1/5th of the population have a CVD risk >20% over the next 10 years. Modern risk scores like the ESC-SCORE2 help to identify those in need of intensified preventive efforts based on basic risk factors like smoking, systolic blood pressure, total cholesterol, age, and sex. According to current ESC-guidelines all men >45 years and all women >55 years should be assessed with SCORE2, which is the best calibrated and validated scoring system for Europe. The calculation of total cardiovascular risk also permits to calculate an individual heart-age, which makes it easier for the individual patient to understand his own risk profile. Most current risk estimation systems can be accessed online under u-prevent.com/calculators. Article published online: 04 August 2023 © 2023. Thieme. All rights reserved. Georg Thieme Verlag KG Rüdigerstraße 14, 70469 Stuttgart, Germany
- 29 March 2023
- Published by Georg Thieme Verlag KG in Aktuelle Kardiologie
- Vol. 12 (02) , 96-101
Stärkung der Prävention: von der Früherkennung bis zur qualifizierten Nachsorge
Aktuelle Versorgungsstudien zeigen eine alarmierende Zunahme lebensstilassoziierter kardiovaskulärer Risikofaktoren (wie Adipositas und körperliche Inaktivität) in der Bevölkerung; eine Verstärkung dieser Entwicklung ist durch die Coronapandemie zu befürchten. Aufklärungsmaßnahmen (insbesondere in Bevölkerungsschichten mit niedrigem sozioökonomischen Status) sowie konsequentes politische Handeln (z. B. beim Nichtraucherschutz oder bei der Steuerung von Ernährungsverhalten) sind deshalb von großer Wichtigkeit. Für die Risikostratifikation und Früherkennung von kardiovaskulären Erkrankungen bei einzelnen Personen empfehlen die aktuellen europäischen Leitlinien SCORE2 unter Beachtung von Risikomodifikatoren (Bildgebung mit Karotis-Ultraschall oder Kardio-CT, psychosoziale und ethnische Faktoren, Begleiterkrankungen). Zukünftig werden voraussichtlich deutlich komplexere Methoden der Risikostratifikation zur Verfügung stehen (insbesondere Genetik und künstliche Intelligenz), die aber derzeit noch nicht für den Routineeinsatz empfohlen werden. In der Nachsorge von Patienten mit manifesten Herz-Kreislauf-Erkrankungen besteht ein großer Verbesserungsbedarf zur nachhaltigen Einstellung der Risikofaktoren. Aktuelle Studien haben die Effektivität von intensiven Langzeit-Präventions-Programmen nachgewiesen, die durch Präventions-Assistent*innen mit ärztlicher Supervision durchgeführt werden. Deshalb wurde im letzten Jahr ein deutschlandweit standardisiertes Curriculum zur Ausbildung von kardiovaskulären Präventions-Assistent*innen eingeführt, die nun in der Praxis die präventivmedizinische Nachsorge der Patienten*innen verbessern können. In recent health care studies an alarming increase of lifestyle-associated risk factors (such as obesity and physical inactivity) was observed in general population; the corona pandemic will increase this development. Therefore, better educational efforts (particularly in populations with low socioeconomic status) and governmental measures (e.g. smoking prevention and regulations for healthy diet) are needed. For cardiovascular screening and risk stratification in individuals, the European guidelines recommend SCORE2 and risk modifiers (imaging by carotid ultrasound or coronary computer tomography, psychosocial and ethnic factors, comorbidities). More complex tools of risk stratification (including genetics, artificial intelligence) can be expected in the future; however, they are currently not recommended for routine use. In most patients with cardiovascular diseases long-term risk factor control does not meet the targets of international guidelines. Intensive prevention programs, performed by prevention assistants under physician supervision, have demonstrated in clinical studies that they are effective to improve risk factor control and reduce events as well as costs. Therefore, a curriculum for cardiovascular prevention assistance was introduced in the last year in Germany as a standard of education for prevention assistants, who can now improve long-term prevention efforts in clinical practice. Article published online: 29 March 2023 © 2023. Thieme. All rights reserved. Georg Thieme Verlag KG Rüdigerstraße 14, 70469 Stuttgart, Germany
- 29 March 2023
- Published by Georg Thieme Verlag KG in Aktuelle Kardiologie
- Vol. 12 (02) , 96-101
Stärkung der Prävention: von der Früherkennung bis zur qualifizierten Nachsorge
Aktuelle Versorgungsstudien zeigen eine alarmierende Zunahme lebensstilassoziierter kardiovaskulärer Risikofaktoren (wie Adipositas und körperliche Inaktivität) in der Bevölkerung; eine Verstärkung dieser Entwicklung ist durch die Coronapandemie zu befürchten. Aufklärungsmaßnahmen (insbesondere in Bevölkerungsschichten mit niedrigem sozioökonomischen Status) sowie konsequentes politische Handeln (z. B. beim Nichtraucherschutz oder bei der Steuerung von Ernährungsverhalten) sind deshalb von großer Wichtigkeit. Für die Risikostratifikation und Früherkennung von kardiovaskulären Erkrankungen bei einzelnen Personen empfehlen die aktuellen europäischen Leitlinien SCORE2 unter Beachtung von Risikomodifikatoren (Bildgebung mit Karotis-Ultraschall oder Kardio-CT, psychosoziale und ethnische Faktoren, Begleiterkrankungen). Zukünftig werden voraussichtlich deutlich komplexere Methoden der Risikostratifikation zur Verfügung stehen (insbesondere Genetik und künstliche Intelligenz), die aber derzeit noch nicht für den Routineeinsatz empfohlen werden. In der Nachsorge von Patienten mit manifesten Herz-Kreislauf-Erkrankungen besteht ein großer Verbesserungsbedarf zur nachhaltigen Einstellung der Risikofaktoren. Aktuelle Studien haben die Effektivität von intensiven Langzeit-Präventions-Programmen nachgewiesen, die durch Präventions-Assistent*innen mit ärztlicher Supervision durchgeführt werden. Deshalb wurde im letzten Jahr ein deutschlandweit standardisiertes Curriculum zur Ausbildung von kardiovaskulären Präventions-Assistent*innen eingeführt, die nun in der Praxis die präventivmedizinische Nachsorge der Patienten*innen verbessern können. In recent health care studies an alarming increase of lifestyle-associated risk factors (such as obesity and physical inactivity) was observed in general population; the corona pandemic will increase this development. Therefore, better educational efforts (particularly in populations with low socioeconomic status) and governmental measures (e.g. smoking prevention and regulations for healthy diet) are needed. For cardiovascular screening and risk stratification in individuals, the European guidelines recommend SCORE2 and risk modifiers (imaging by carotid ultrasound or coronary computer tomography, psychosocial and ethnic factors, comorbidities). More complex tools of risk stratification (including genetics, artificial intelligence) can be expected in the future; however, they are currently not recommended for routine use. In most patients with cardiovascular diseases long-term risk factor control does not meet the targets of international guidelines. Intensive prevention programs, performed by prevention assistants under physician supervision, have demonstrated in clinical studies that they are effective to improve risk factor control and reduce events as well as costs. Therefore, a curriculum for cardiovascular prevention assistance was introduced in the last year in Germany as a standard of education for prevention assistants, who can now improve long-term prevention efforts in clinical practice. Article published online: 29 March 2023 © 2023. Thieme. All rights reserved. Georg Thieme Verlag KG Rüdigerstraße 14, 70469 Stuttgart, Germany